CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 686 enrolled
Drug / intervention
Curcumin +1 moredrug
Likely dose
Curcumin 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01246973
NCT01246973Phase 3Completed
CompareCT.gov

Oral Curcumin for Radiation Dermatitis in Breast Cancer Patients

University of Rochester·interventional·Posted Nov 24, 2010·Updated Mar 7, 2016

In Brief

A Phase 3 clinical trial evaluating Curcumin and Placebo for Radiation-induced Dermatitis. Completed, enrolled 686 participants.

Detailed Summary

The purpose of the study is to determine whether curcumin, an ingredient of some foods, can prevent or reduce the severity of skin reactions (dermatitis) caused by radiation therapy. Dermatitis is a common side effect of radiation treatment, but few effective treatments have been developed for it. Curcumin is a natural compound found in both turmeric and curry powder. It has been used for centuries as a spice (curry), a food coloring and as a food preservative. Curcumin is non-toxic and has been found to enhance the functions of normal tissues..

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRadiation-induced Dermatitis
Countries--
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 24, 2010
Enrollment StartFeb 1, 2011
Primary CompletionNov 1, 2014
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 15.6 years ago

Interventions

Curcumindrug

4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week

Placebodrug

4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week